Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1. / Sesé, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Fuentes, Pedro (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Esteve-Codina, Anna (CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Universitat Pompeu Fabra, Barcelona, Spain) ; Béjar, Eva (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; McGrail, Kimberley (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Thomas, George (Physiological Sciences Department, Faculty of Medicine and Health Science, University of Barcelona, Barcelona, Spain) ; Aasen, Trond (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Ramón y Cajal, Santiago (Hospital Universitari Vall d'Hebron. Institut de Recerca) ; Universitat Autònoma de Barcelona
Breast cancer is the most prevalent malignancy in women and there is an urgent need for new therapeutic drugs targeting aggressive and metastatic subtypes, such as hormone-refractory triple-negative breast cancer (TNBC). [...]
2017 - 10.18632/oncotarget.23145
Oncotarget, Vol. 8 (december 2017) , p. 114856-114876  
21 p, 5.1 MB
2.
39 p, 4.7 MB mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer / Zabala Letona, Amaia (CIBERONC) ; Arruabarrena Aristorena, Amaia (CIC bioGUNE) ; Martín Martín, Natalia (CIBERONC) ; Fernández Ruiz, Sonia (CIBERONC) ; Sutherland, James D. (CIC bioGUNE) ; Clasquin, Michelle (AGIOS Pharmaceuticals) ; Tomás Cortázar, Julen (CIC bioGUNE) ; Jiménez, José (Hospital Universitari Vall d'Hebron) ; Torres Ramírez, Inés Ma. de (Hospital Universitari Vall d'Hebron) ; Quang, Phong (AGIOS Pharmaceuticals) ; Ximénez Embun, Pilar (Spanish National Cancer Research Centre) ; Bago, Ruzica (MRC Protein Phosphorylation and Ubiquitylation Unit) ; Ugalde Olano, Aitziber (Basurto University Hospital) ; Loizaga Iriarte, Ana (Basurto University Hospital) ; Lacasa Viscasillas, Isabel (Basurto University Hospital) ; Unda, Miguel (Basurto University Hospital) ; Torrano, Verónica (CIBERONC) ; Cabrera, Diana (CIC bioGUNE) ; van Liempd, Sebastiaan M. (CIC bioGUNE) ; Cendon, Ylenia (Universidad Autónoma de Madrid) ; Castro, Elena (Spanish National Cancer Research Centre) ; Murray, Stuart (AGIOS Pharmaceuticals) ; Revandkar, Ajinkya (University of Lausanne) ; Alimonti, Andrea (University of Lausanne) ; Zhang, Yinan (Harvard School of Public Health) ; Barnett, Amelia (AGIOS Pharmaceuticals) ; Lein, Gina (AGIOS Pharmaceuticals) ; Pirman, David (AGIOS Pharmaceuticals) ; Cortázar, Ana R. (CIC bioGUNE) ; Arreal, Leire (CIC bioGUNE) ; Prudkin, Ludmila (Hospital Universitari Vall d'Hebron) ; Astobiza, Ianire (CIC bioGUNE) ; Valcárcel Jiménez, Lorea (CIC bioGUNE) ; Zúñiga García, Patricia (CIC bioGUNE) ; Fernández Domínguez, Itziar (CIC bioGUNE) ; Piva, Marco (CIC bioGUNE) ; Caro Maldonado, Alfredo (CIC bioGUNE) ; Sánchez Mosquera, Pilar (CIC bioGUNE) ; Castillo Martín, Mireia (Fundação Champalimaud) ; Serra, Violeta (Hospital Universitari Vall d'Hebron) ; Beraza, Naiara (CIC bioGUNE) ; Gentilella, Antonio (Catalan Institute of Oncology) ; Thomas, George (Catalan Institute of Oncology) ; Azkargorta, Mikel (Carlos III Networked Proteomics Platform) ; Elortza, Felix (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Farràs, Rosa (Centro de Investigación Príncipe Felipe) ; Olmos, David (Hospitales Universitarios Virgen de la Victoria y Regional de Málaga) ; Efeyan, Alejo (Spanish National Cancer Research Centre) ; Anguita, Juan (Ikerbasque) ; Muñoz, Javier (Carlos III Networked Proteomics Platform) ; Falcón Pérez, Juan M. (Ikerbasque) ; Barrio, Rosa (CIC bioGUNE) ; Macarulla Mercadé, Teresa (Hospital Universitari Vall d'Hebron) ; Mato, José M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Martínez Chantar, Maria L. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Cordon Cardo, Carlos (Icahn School of Medicine at Mount Sinai) ; Aransay, Ana M. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas) ; Marks, Kevin (AGIOS Pharmaceuticals) ; Baselga Torres, Josep, 1959-, (Memorial Sloan-Kettering Cancer Center) ; Taberneroo, J (Hospital Universitari Vall d'Hebron) ; Nuciforo, Paolo (Hospital Universitari Vall d'Hebron) ; Manning, Brendan D. (Harvard School of Public Health) ; Marjon, Katya (AGIOS Pharmaceuticals) ; Carracedo, Arkaitz (University of the Basque Country) ; Universitat Autònoma de Barcelona
Activation of the PTEN-PI3K-mTORC1 pathway consolidates metabolic programs that sustain cancer cell growth and proliferation,. Here we show that mTORC1 regulates polyamine dynamics, a metabolic route that is essential for oncogenicity. [...]
2017 - 10.1038/nature22964
Nature, Vol. 547 (July 2017) , p. 109-113  
3.
13 p, 3.4 MB Effect of low doses of actinomycin D on neuroblastoma cell lines / Cortes, Constanza L. (Laboratory of Cancer Metabolism, IDIBELL, Hospital Duran i Reynals) ; Veiga, Sonia R. (Laboratory of Cancer Metabolism, IDIBELL, Hospital Duran i Reynals, 08908 L'Hospitalet de Llobregat) ; Almacellas, Eugènia (Laboratory of Cancer Metabolism, IDIBELL, Hospital Duran i Reynals) ; Javier Hernández-Losa (Hospital Vall d'Hebron. Departament de Patologia) ; Ferreres, Joan C. (Hospital Vall d'Hebron. Departament de Patologia) ; Kozma, Sara C. (Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati) ; Ambrosio, Santiago (Unit de Biochemistry, Department of Physiological Sciences II, Faculty of Medicine, Campus Universitari de Bellvitge - IDIBELL, University of Barcelona) ; Thomas, George (Unit de Biochemistry, Department of Physiological Sciences II, Faculty of Medicine, Campus Universitari de Bellvitge - IDIBELL, University of Barcelona) ; Tauler, Albert (Laboratory of Cancer Metabolism, IDIBELL, Hospital Duran i Reynals) ; Universitat Autònoma de Barcelona
Neuroblastoma is a malignant embryonal tumor occurring in young children, consisting of undifferentiated neuroectodermal cells derived from the neural crest. Current therapies for high-risk neuroblastoma are insufficient, resulting in high mortality rates and high incidence of relapse. [...]
2016 - 10.1186/s12943-015-0489-8
Molecular Cancer, Vol. 15 (january 2016)  

Vea también: autores con nombres similares
2 Thomas, G.
1 Thomas, Gareth J.
1 Thomas, Gregg W. C.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.